CKPT — Checkpoint Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $345.11m
- $338.50m
- $0.04m
Annual income statement for Checkpoint Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.07 | 0.268 | 0.192 | 0.103 | 0.041 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 24.3 | 57 | 58.5 | 52.3 | 56.2 |
| Operating Profit | -23.2 | -56.7 | -58.3 | -52.1 | -56.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -23.1 | -56.7 | -62.6 | -51.8 | -56.2 |
| Net Income After Taxes | -23.1 | -56.7 | -62.6 | -51.8 | -56.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -23.1 | -56.7 | -62.6 | -51.8 | -56.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -23.1 | -56.7 | -62.6 | -51.8 | -56.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -4.13 | -7.45 | -7.09 | -2.77 | -1.42 |